Pages that link to "Q59650903"

The following pages link to High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects (Q59650903):

Displaying 33 items.

• Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients (Q24602593) (← links)
• The aftermath of the Merck's HIV vaccine trial (Q24654458) (← links)
• Poxvirus vectors as HIV/AIDS vaccines in humans (Q26995078) (← links)
• The evolution of poxvirus vaccines (Q26995905) (← links)
• Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates (Q27489500) (← links)
• A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy (Q33645564) (← links)
• Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054) (Q33737476) (← links)
• Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons (Q33881052) (← links)
• The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay (Q34066932) (← links)
• Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa (Q34229329) (← links)
• The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice (Q34428899) (← links)
• Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants (Q34592982) (← links)
• CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8 T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals (Q34692141) (← links)
• Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles (Q34772727) (← links)
• Human immunodeficiency virus vaccines (Q35674731) (← links)
• Vaccine-delivered HIV envelope inhibits CD4( ) T-cell activation, a mechanism for poor HIV vaccine responses (Q35750908) (← links)
• Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors (Q35857215) (← links)
• Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors (Q35914427) (← links)
• HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice (Q36156347) (← links)
• Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults (Q36172965) (← links)
• Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial (Q36618096) (← links)
• Progress and obstacles in the development of an AIDS vaccine (Q36662462) (← links)
• Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants (Q37643303) (← links)
• Novel HIV vaccine strategies: overview and perspective (Q37668399) (← links)
• Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans (Q37799412) (← links)
• OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8 T‐cell vaccines against respiratory viruses (Q37948126) (← links)
• Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions (Q42800541) (← links)
• Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination (Q43125298) (← links)
• Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults (Q45398885) (← links)
• Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers (Q48036553) (← links)
• The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine (Q51955521) (← links)
• Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. (Q54520826) (← links)
• Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection (Q64375778) (← links)